Purchase this article with an account.
Barbara Wilhelm, Andreas Koegel, Nadine Kahle, Tobias Peters, Stylianos Michalakis, Martin Biel, Mathias Seeliger, Eberhart Zrenner, Bernd Wissinger, Susanne Kohl, Marius Ueffing, Karl Ulrich Bartz-Schmidt, Dominik M Fischer, Ditta Zobor; How do patients rate their subjective symptoms after CNGA3 gene therapy: First application of the instrument A3-PRO. Invest. Ophthalmol. Vis. Sci. 2017;58(8):4678.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
There are limitations of wide-spread standard measures for vision-oriented quality of life like the VFQ25. Specific symptoms in low vision caused by hereditary disorders and their short-term variations during an interventional trial may not be sufficiently reflected. This is especially true for Achromatopsia, a hereditary retinal degeneration with severe visual impairment in daily life, its leading symptom being glare in normal daylight conditions. Our aim was to develop a patient reported outcome (PRO) measure as a complement to the VFQ25 in the first gene therapy trial in CNGA3-linked Achromatopsia.
A3-PRO is a short questionnaire to measure the patients’ subjective visual performance and its development during therapy in a clinical trial, using five criteria – each represented by a single item. In order to also consider the possibility of sporadic deteriorations we provided a symmetric response scale, although distinctive declines were not expected. The patients rate the development of all aspects on a scale ranging from “almost always worse” (-4) to “almost always better” (+4) in nine indicated steps, including “unchanged” (0) as middle category. The questions are read by an interviewer, so the questionnaire contains a brief instruction and supplementary explanations to each item. The inventory is completed by a simple five-level scale of the patient’s overall satisfaction with the therapy. The questions were deduced from the key symptoms identified in an observational trial in the target cohort.
A3-PRO was easy to assess for both patient and interviewer. The time need was appr. five minutes per test. Interim results of the ongoing trial (n=9; 1 f, 8 m; age range: 24 to 59 y) are reported (NCT02610582). The questionnaire was able to reflect intra- and interindividual changes of subjective symptoms over the time of the study in all three dosage groups. Our preliminary findings need to be confirmed in the final analysis.
A3-PRO is an easy applicable tool for the investigation of Achromatopsia. It provides valuable quantitative data on patient perception of symptom development after treatment and is superior to open, non-standardized questions in the clinical trial setting.
This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.
This PDF is available to Subscribers Only